Hi Herny,
Picked this up about the conference...Rich
Companies See Vast Opportunities in World Cancer Therapeutic Market 08:05 a.m. Jan 06, 1997 EST
MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire/ -- With an increasing incidence rate and with no cure expected in the foreseeable future, cancer is projected to become the number-one killer in industrialized countries by the year 2000. The American Cancer Society estimates that the U.S. spends over $104 billion every year to fight the disease.
For these reasons, strategic research conducted by the international marketing consulting firm, Frost & Sullivan, forecasts that biotechnology and pharmaceutical manufacturers will continue to concentrate their efforts on this market, whose revenues (excluding adjuncts) are estimated to reach $7.4 billion by the end of 1996.
"World Cancer Therapeutic Markets - A Product-Based Analysis" explores the major existing and emerging cancer therapeutics, such as cytotoxics, immunological therapies, novel therapies and cancer adjuncts.
"The proliferation of new cancer drugs, combined with the need for new cancer adjuncts, is driving the growth of the cancer pharmaceutical therapeutics market," said Frost & Sullivan medical industry research manager, Nina Giles. According to Giles, with over 200 cancer products in development and new treatments emerging all the time, cancertherapeutics will undergo a dramatic change.
"Because cancer is mostly a disease of the aging, the overall 'graying' of the population combined with the fact that there is not yet an effective "cure," for the disease makes the cancer market one of the most important in the pharmaceutical industry," Giles said.
Recent changes in healthcare have also changed the market. In the current healthcare environment, providers are placing the most importance on the cost and the outcomes of cancer care. Therefore, the companies that are able to track these factors are the ones that are most likely to be successful. Patients are most interested in treatments that may be expensive, but provide the best outcomes in the long run.
The increased emphasis on biotechnology is another factor that is changing cancer therapeutics. Treatments are now focusing more on the molecular and cellular levels, in an effort to understand the genetic basis of the disease. As this understanding is achieved, technologies will be able to function on a more individual level, basing treatment on basic genetic information.
As pharmaceutical and biotechnology markets expand globally, and cancer-treating technologies and products diversify, it is becoming more difficult for companies to capture market share. Therefore, strategic alliances have become more important, reducing product development risk and cost, while increasing the company's product pipeline.
Cytotoxic agents are the standard pharmacological treatment for most cancers, but their use is declining as they can cause a range of negative side-effects. Immunological therapies use
substances from the immune system to fight the disease, and the side-effects are less severe. Novel therapies target the cancer and are used in conjunction with cytotoxic agents, maximizing the effectiveness while minimizing side-effects. Cancer adjuncts are used to treat any adverse reactions to cancer therapy.
Products and technologies covered in this study include: Cytotoxins, hormonal cancer therapies, alkylating agents, antibiotic antineoplastics, antimetabolites, immunological cancer therapies, interferons, interleukins, novel cancer therapies, monoclonal antibodies, liposomes, cancer adjuncts, antiemetics, antinauseants and growth factors.
Companies participating in this market include: A.H. Robins, Abbott Laboratories, Allergan Inc., Amersham MediPhysics, Amgen Inc., Astra AD, Astra USA Inc., Barr Laboratories Inc., Barre-National Inc. (now called Alpharma), Bayer Corporation/Pharmaceutical Division, Biocraft Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Carnrick Laboratories Inc., Central Pharmaceuticals Inc., Chiron Corporation, Chugai Pharmaceutical Co. Ltd., Ciba Pharmaceuticals, Connaught Laboratories Inc., Duramed Pharmaceuticals Inc., Eli Lilly & Company, Elkins-Sinn Inc. Erbamont, Glaxo Wellcome Inc., Hoffman-La Roche, ICN Pharmaceuticals Inc., Immunex Corporation, Janssen Pharmaceuticals Inc., Kyowa Hakko Kogyo Co. Ltd., Lederle Laboratories, Lundbeck, May & Baker, Mayrand Pharmaceuticals, Meiji Seika, Merck & Co. Inc., MGI PHARMA INC., Muro
Pharmaceuticals Inc., Mylan Pharmaceuticals, NeXstar Pharmaceuticals Inc., Nippon Kayaku Co. Ltd., Organon Inc., Ortho Biotech Inc., Ortho McNeil Pharmaceutical Corporation, Par Pharmaceutical Inc., Parke-Davis Group, Pfizer Inc., Pharmacia & Upjohn Inc., Pharmacia Therapeutics, Pierre Fabre Medicament, Rhone-Poulenc Rorer Pharmaceuticals, Roberts Pharmaceutical Corp., Roerig Division, Roxane Laboratories Inc., Sankyo Co. Ltd., Sanofi Winthrop Pharmaceuticals, Schein Pharmaceuticals Inc., Schering AG, Schering-Plough Laboratories, Sequus Pharmaceuticals, Shionogi & Co., SmithKline Beecham, SoloPak Pharmaceuticals Inc., Solvay Pharmaceuticals, Star
Pharmaceuticals Inc., Sumitomo Pharmaceuticals, Taiho Pharmaceuticals, Takeda Chemical Industries Ltd., TAP Pharmaceuticals Inc., Tokyo Tanabe, US Bioscience Inc., Warner Chilcott Inc., Watson Pharmaceuticals Inc., Wyeth-Ayerst Laboratories, Yamanouchi Pharmaceutical Co. Ltd., Zeneca Pharmaceuticals, Alfacell Corp., American Cyanamid Co., Aphton Corporation, Ares-Serono Group, Aronex Pharmaceuticals Incorporated, Asta Medica AG, Berlex Laboratories, Biomira Incorporated, Boehringer Ingelheim Pharmaceutical Inc., British Biotech Pharmaceuticals Ltd., Cellcor Therapies Inc., Chiron/Viagene Inc., Ciba-Giegy Corp., CYTOGEN Corp., Daiichi Pharmaceutical Co. Ltd., Du Pont Merck Pharmaceutical Company, Elan Pharma, Faulding Pharmaceuticals, Genentech Inc., Genetix Pharmaceuticals Inc., Hyal Pharmaceutical Corp., Ilex Oncology Inc., ImClone Systems Inc., Immune Response Corporation (The), Immuno Therapeutics Inc., Immunomedics Inc., Interferon Sciences Inc., Johnson & Johnson Medical Inc., Johnson Matthey Inc., Ligand Pharmaceuticals, Matrix Pharmaceutical Inc., Medac GmbH, Medarex Inc., MicroGeneSys Inc., National Cancer Institute, National Institutes of Health, NeXstar Pharmaceuticals, Pasteur Merieux, R.W. Johnson Pharmaceuticals, Repligen Corporation, Ribi ImmunoChem Research Inc.,
Roberts Pharmaceutical Corp., Sanofi Winthrop Pharmaceuticals, Schering-Plough Corporation, Sequus Pharmaceuticals, Seragen Inc., Serono Laboratories Inc., SmithKline Beecham Pharmaceuticals, Targeted Genetics Corp., Techniclone International Corp., Therion Biologics Corporation, and Warner-Lambert Company.
Frost & Sullivan is an international marketing consulting company that monitors the medical industry for market trends, market measurements, and strategies. This ongoing research is utilized to update a series of research publications such as #5345-54, "U.S. Breast Cancer Diagnostics, Therapeutics and Prosthetics Markets," and to support industry participants with customized consulting needs.
Report: 5224-52 Publish Date: February 1996 Price: $2495
SOURCE Frost & Sullivan |
